{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:46:00Z","timestamp":1793965560090,"version":"4.8.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,8]]},"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p>Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA)\u00a0\u00d7 CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with relapsed\/refractory multiple myeloma (R\/RMM). As a T-cell redirection therapy, clinical outcomes with teclistamab may be influenced by patient immune fitness and tumor antigen expression. We correlated tumor characteristics and baseline immune profiles with clinical response and disease burden in patients with R\/RMM from the pivotal phase 1\/2 MajesTEC-1 study, focusing on patients treated with 1.5 mg\/kg of teclistamab (N\u00a0= 165). Peripheral blood samples were collected at screening, and bone marrow samples were collected at screening and cycle 3. Better clinical outcomes to teclistamab correlated with higher baseline total T-cell counts in the periphery. In addition, responders (partial response or better) had a lower proportion of immunosuppressive regulatory T cells (Tregs), T cells expressing coinhibitory receptors (CD38, PD-1, and PD-1\/TIM-3), and soluble BCMA and a T-cell profile suggestive of a more cytolytic potential, compared with nonresponders. Neither frequency of baseline bone marrow BCMA expression nor BCMA-receptor density was associated with clinical response to teclistamab. Improved progression-free survival was observed in patients with a lower frequency of T cells expressing exhaustion markers and immunosuppressive Tregs. Overall, response to teclistamab was associated with baseline immune fitness; nonresponders had immune profiles suggestive of immune suppression and T-cell dysfunction. These findings illustrate the importance of the contribution of the immune landscape to T-cell redirection therapy response. This trial was registered at www.ClinicalTrials.gov as #NCT03145181\/NCT04557098.<\/jats:p><\/jats:sec>","DOI":"10.1182\/blood.2023022823","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T20:03:40Z","timestamp":1713989020000},"page":"615-628","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":76,"title":["Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study"],"prefix":"10.1182","volume":"144","author":[{"given":"Diana","family":"Cortes-Selva","sequence":"first","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Perova","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Skerget","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Stein","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengasamy","family":"Boominathan","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onsay","family":"Lau","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Calara-Nielsen","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuc","family":"Davis","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaymala","family":"Patel","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnob","family":"Banerjee","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Stephenson","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Uhlar","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[{"name":"2Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Goldberg","sequence":"additional","affiliation":[{"name":"2Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Pei","sequence":"additional","affiliation":[{"name":"2Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Trancucci","sequence":"additional","affiliation":[{"name":"2Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Girgis","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2013-372X","authenticated-orcid":false,"given":"Shun Xin","family":"Wang Lin","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviawati S.","family":"Wu","sequence":"additional","affiliation":[{"name":"3Janssen Research & Development, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"4University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"5Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"6Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"7Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-4341","authenticated-orcid":false,"given":"Raluca I.","family":"Verona","sequence":"additional","affiliation":[{"name":"1Janssen Research & Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2024080815204223000_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"2024080815204223000_bib2","doi-asserted-by":"crossref","first-page":"1178224219868235","DOI":"10.1177\/1178224219868235","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"issue":"11","key":"2024080815204223000_bib3","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"25","key":"2024080815204223000_bib4","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024080815204223000_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024080815204223000_bib6","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024080815204223000_bib7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2024080815204223000_bib8","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"2024080815204223000_bib9","author":"TECVAYLI","year":"2022"},{"key":"2024080815204223000_bib10","author":"TECVAYLI","year":"2022"},{"issue":"18","key":"2024080815204223000_bib11","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"issue":"10301","key":"2024080815204223000_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u00a0\u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2024080815204223000_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024080815204223000_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"issue":"4","key":"2024080815204223000_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"2024080815204223000_bib16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Front Immunol"},{"key":"2024080815204223000_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fcell.2020.00017","article-title":"T cell dysfunction and exhaustion in cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"2024080815204223000_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"issue":"3","key":"2024080815204223000_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"issue":"8","key":"2024080815204223000_bib20","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.3390\/cancers13081776","article-title":"Activated regulatory T-cells, dysfunctional and senescent T-cells hinder the immunity in pancreatic cancer","volume":"13","author":"Sivakumar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"18","key":"2024080815204223000_bib21","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2024080815204223000_bib22","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024080815204223000_bib23","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/cancers13092018","article-title":"Overcoming the immunosuppressive tumor microenvironment in multiple myeloma","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024080815204223000_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","article-title":"Immunomodulatory effects of CD38-targeting antibodies","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett"},{"key":"2024080815204223000_bib25","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"issue":"15","key":"2024080815204223000_bib26","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2024080815204223000_bib27","doi-asserted-by":"crossref","first-page":"636375","DOI":"10.3389\/fimmu.2021.636375","article-title":"Bystander memory T cells and IMiD\/checkpoint therapy in multiple myeloma: a dangerous tango?","volume":"12","author":"Sponaas","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2024080815204223000_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T\u00a0cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"issue":"5","key":"2024080815204223000_bib29","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1097\/HS9.0000000000000881","article-title":"NK cell phenotype is associated with response and resistance to daratumumab in relapsed\/refractory multiple myeloma","volume":"7","author":"Verkleij","year":"2023","journal-title":"HemaSphere"},{"issue":"6","key":"2024080815204223000_bib30","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00277-023-05603-w","article-title":"Immune profiling of patients with extranodal natural killer\/T cell lymphoma treated with daratumumab","volume":"103","author":"Qing","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"2024080815204223000_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbmt.2019.08.009","article-title":"T\u00a0cell\u00a0transcriptional profiling and immunophenotyping uncover LAG3 as a potential significant target of immune modulation in multiple myeloma","volume":"26","author":"Lucas","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024080815204223000_bib32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2024080815204223000_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/adt.2020.1024","article-title":"A\u00a0flexible multiplatform bioanalytical strategy for measurement of total circulating shed target receptors: application to soluble B cell maturation antigen levels in the presence of a bispecific antibody drug","volume":"19","author":"Stauffer","year":"2021","journal-title":"Assay Drug Dev Technol"},{"issue":"5","key":"2024080815204223000_bib34","doi-asserted-by":"crossref","first-page":"e002254","DOI":"10.1136\/jitc-2020-002254","article-title":"Pre-existing immune status associated with response to combination of sipuleucel-T and\u00a0ipilimumab in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"Sinha","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"2024080815204223000_bib35","doi-asserted-by":"crossref","first-page":"118368","DOI":"10.1016\/j.lfs.2020.118368","article-title":"An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer","volume":"261","author":"Li","year":"2020","journal-title":"Life Sci"},{"issue":"9","key":"2024080815204223000_bib36","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2024080815204223000_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17474086.2023.2154648","article-title":"Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States","volume":"16","author":"Varughese","year":"2022","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2024080815204223000_bib38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2141.2000.02131.x","article-title":"T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells","volume":"110","author":"Raitakari","year":"2000","journal-title":"Br J Haematol"},{"issue":"41","key":"2024080815204223000_bib39","doi-asserted-by":"crossref","first-page":"17469","DOI":"10.1073\/pnas.0907448106","article-title":"Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity","volume":"106","author":"Hinrichs","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024080815204223000_bib40","doi-asserted-by":"crossref","first-page":"28208","DOI":"10.1038\/srep28208","article-title":"Na\u00efve CD8(+) T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-\u03b2 immunosuppression in the tumor microenvironment","volume":"6","author":"Nguyen","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"2024080815204223000_bib41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2024080815204223000_bib42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cyto.a.22351","article-title":"From \u201ctruly na\u00efve\u201d to \u201cexhausted senescent\u201d T cells: when markers predict functionality","volume":"85","author":"Larbi","year":"2014","journal-title":"Cytometry A"},{"issue":"1","key":"2024080815204223000_bib43","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/s41467-017-01728-5","article-title":"Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA","volume":"8","author":"Tian","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2024080815204223000_bib44","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.3324\/haematol.2019.219683","article-title":"Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed\/refractory multiple myeloma patients","volume":"105","author":"Kitadate","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2024080815204223000_bib45","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/ijo.2016.3524","article-title":"Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma","volume":"49","author":"Niccolai","year":"2016","journal-title":"Int J Oncol"},{"issue":"11","key":"2024080815204223000_bib46","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"9","key":"2024080815204223000_bib47","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.clml.2020.03.012","article-title":"Increased bone marrow plasma-cell percentage predicts outcomes in newly diagnosed multiple myeloma patients","volume":"20","author":"Al Saleh","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"2024080815204223000_bib48","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024080815204223000_bib49","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/6\/615\/2237324\/blood_bld-2023-022823-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/6\/615\/2237324\/blood_bld-2023-022823-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T23:48:50Z","timestamp":1731800930000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/6\/615\/515889\/Correlation-of-immune-fitness-with-response-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022823","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}